|
May 06, 2021
|
Dynavax Announces First Quarter 2021 Financial Results
|
|
|
May 04, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Apr 27, 2021
|
HEPLISAV-B Post-Marketing Observational Study Results Presented at 2021 Annual Conference on Vaccinology Research (ACVR)
|
|
|
Apr 22, 2021
|
Dynavax to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021
|
|
|
Apr 21, 2021
|
Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax's CpG 1018™ Adjuvant
|
|
|
Apr 19, 2021
|
Two HEPLISAV-B Abstracts Selected for Oral Presentation at the 2021 Annual Conference on Vaccinology Research (ACVR)
|
|
|
Apr 06, 2021
|
Positive Phase 1/2 Results for Valneva's Inactivated COVID-19 Vaccine Candidate Using Dynavax's CpG 1018™ Adjuvant
|
|
|
Apr 02, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Mar 24, 2021
|
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
|
|
|
Mar 01, 2021
|
Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
|
|
